Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disubstituted pyrimidines as Lck inhibitors.
Hunt JA, Beresis RT, Goulet JL, Holmes MA, Hong XJ, Kovacs E, Mills SG, Ruzek RD, Wong F, Hermes JD, Park YW, Salowe SP, Sonatore LM, Wu L, Woods A, Zaller DM, Sinclair PJ. Hunt JA, et al. Among authors: zaller dm. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5440-3. doi: 10.1016/j.bmcl.2009.07.102. Epub 2009 Jul 25. Bioorg Med Chem Lett. 2009. PMID: 19674899
p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones.
Hunt JA, Kallashi F, Ruzek RD, Sinclair PJ, Ita I, McCormick SX, Pivnichny JV, Hop CE, Kumar S, Wang Z, O'Keefe SJ, O'Neill EA, Porter G, Thompson JE, Woods A, Zaller DM, Doherty JB. Hunt JA, et al. Among authors: zaller dm. Bioorg Med Chem Lett. 2003 Feb 10;13(3):467-70. doi: 10.1016/s0960-894x(02)00990-3. Bioorg Med Chem Lett. 2003. PMID: 12565952
p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones.
Bao J, Hunt JA, Miao S, Rupprecht KM, Stelmach JE, Liu L, Ruzek RD, Sinclair PJ, Pivnichny JV, Hop CE, Kumar S, Zaller DM, Shoop WL, O'neill EA, O'keefe SJ, Thompson CM, Cubbon RM, Wang R, Zhang WX, Thompson JE, Doherty JB. Bao J, et al. Among authors: zaller dm. Bioorg Med Chem Lett. 2006 Jan 1;16(1):64-8. doi: 10.1016/j.bmcl.2005.09.065. Epub 2005 Oct 18. Bioorg Med Chem Lett. 2006. PMID: 16242322
The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.
Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Tang W, Bansal A, Cummings RT, Cunningham BR, Friedlander AM, Douglas CM, Salowe SP, Zaller DM, Scolnick EM, Schmatz DM, Bartizal K, Hermes JD, MacCoss M, Chapman KT. Xiong Y, et al. Among authors: zaller dm. Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8. doi: 10.1016/j.bmcl.2005.10.088. Epub 2005 Dec 9. Bioorg Med Chem Lett. 2006. PMID: 16338135
Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti SL, Frie JL, Dixon EC, Singh SB, Choi BK, Scapin G, Fitzgerald CE, Kumar S, Nichols EA, O'Keefe SJ, O'Neill EA, Porter G, Samuel K, Schmatz DM, Schwartz CD, Shoop WL, Thompson CM, Thompson JE, Wang R, Woods A, Zaller DM, Doherty JB. Colletti SL, et al. Among authors: zaller dm. J Med Chem. 2003 Jan 30;46(3):349-52. doi: 10.1021/jm025585h. J Med Chem. 2003. PMID: 12540232
Anthrax lethal factor inhibition.
Shoop WL, Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Felcetto T, Michael BF, Bansal A, Cummings RT, Cunningham BR, Friedlander AM, Douglas CM, Patel SB, Wisniewski D, Scapin G, Salowe SP, Zaller DM, Chapman KT, Scolnick EM, Schmatz DM, Bartizal K, MacCoss M, Hermes JD. Shoop WL, et al. Among authors: zaller dm. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7958-63. doi: 10.1073/pnas.0502159102. Epub 2005 May 23. Proc Natl Acad Sci U S A. 2005. PMID: 15911756 Free PMC article.
SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors.
Liu L, Stelmach JE, Natarajan SR, Chen MH, Singh SB, Schwartz CD, Fitzgerald CE, O'Keefe SJ, Zaller DM, Schmatz DM, Doherty JB. Liu L, et al. Among authors: zaller dm. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3979-82. doi: 10.1016/j.bmcl.2003.08.059. Bioorg Med Chem Lett. 2003. PMID: 14592489
p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold.
Natarajan SR, Wisnoski DD, Singh SB, Stelmach JE, O'Neill EA, Schwartz CD, Thompson CM, Fitzgerald CE, O'Keefe SJ, Kumar S, Hop CE, Zaller DM, Schmatz DM, Doherty JB. Natarajan SR, et al. Among authors: zaller dm. Bioorg Med Chem Lett. 2003 Jan 20;13(2):273-6. doi: 10.1016/s0960-894x(02)00876-4. Bioorg Med Chem Lett. 2003. PMID: 12482438
64 results